HomeAI · summaries
Storia in 3 fonti
CagriSema confers ‘high magnitude’ of HbA1c, weight reductions in type 2 diabetes
NEW ORLEANS —A once-weekly combination therapy of cagrilintide and semaglutide reduced HbA1c and body weight across a wide range of adults with type 2 diabetes, according to data from three phase 3 trials. CagriSema (Novo Nordisk) is a combination drug consisting of the long-acting amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide (Ozempic/Wegovy). During
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to…
People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than…
- ·
Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications
